**Abstract**

**Objective:** We suggested that the cognitive impairment induced by repeated MA treatment in mice is a useful model of the cognitive deficits in schizophrenia and MA psychosis. We also demonstrated that minocycline, an antibiotic possessing anti-inflammatory activity, improves cognitive impairment induced by MA. It is well-known that protein kinase C (PKC) mediates neuroinflammation. Therefore, we investigated a specific role of PKC in response to cognitive impairment induced by MA.

**Method**: To achieve a better understanding whether PKC expression can be altered by repeated treatment with MA. We examined changes in the expression of PKCα, PKCβ~1~, PKCβ~2~, PKCζ, and PKCδ in the prefrontal cortex (PFC) after the final MA treatment. Because PKCδ expression is selectively increased after the last MA, we applied PKCδ knock-out (KO) mice in this study. We evaluated relationship between novel object recognition test (NORT), phosphorylation of extracellular signal-regulated kinase ½ (p-ERK½), and phosphorylation of PKCδ (p-PKCδ) in the PFC.

**Result**: Repeated treatment with MA resulted in cognitive impairment as evaluated by NORT. This effect lasted, at least, for 28 days after the final MA treatment. Correlation study indicated that cognitive impairment parallels p-PKCδ expression. P-ERK½ expression increased in the mice exposed to the novel objects in the absence of MA, but it was decreased in the presence of MA. Genetic inhibition of PKCδ attenuated MA-induced decrease in p-ERK½ expression. Posttreatment with antipsychotic clozapine significantly protected cognitive impairment and alteration in p-ERK½ and p-PKCδ.

**Conclusion:** PKCδ gene is an endogenous neuropsychostimulant for behavioral side effects and cognitive impairment induced by MA. Interestingly, clozapine positively modulated p-ERK½ and p-PKCδ induced by MA in the PFC of mice \[This study was supported by a grant (14182MFDS979) from the Korea Food and Drug Administration, Republic of Korea\].
